Rapport Therapeutics, Inc. shares its Q3 performance and future strategies in its latest filing, emphasizing growth in the pharmaceutical sector.
| Name | Rapport Therapeutics, Inc. |
|---|---|
| CIK | 0002012593 |
| Tickers | RAPP |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 880724208 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 857-321-8020 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Rapport Therapeutics, Inc. shares its Q3 performance and future strategies in its latest filing, emphasizing growth in the pharmaceutical sector.
Rapport Therapeutics, Inc. shares Q3 2026 financial results and business highlights, signaling ongoing developments in the pharmaceutical sector.
James Healy, director of Rapport Therapeutics, acquires significant shares, signaling confidence in the company's future amid industry trends.
Rapport Therapeutics has raised $382.5 million through a public offering of common stock and convertible senior notes to fund clinical trials and research.
Rapport Therapeutics announces a $150 million public offering of convertible senior notes due 2032, aiming to strengthen its financial position.
Rapport Therapeutics, Inc. announces a public offering to raise $200 million through shares and pre-funded warrants, enhancing its financial position.
Rapport Therapeutics announces a $200 million capital raise through stock and convertible notes offerings to fund clinical trials and research.
Rapport Therapeutics reveals pricing for $175M in stock and $150M in convertible notes to fund clinical trials and research initiatives.
Rapport Therapeutics, Inc. files a prospectus for a public offering of common stock and pre-funded warrants to fund clinical trials and R&D.
Rapport Therapeutics, Inc. has announced a public offering of convertible senior notes due 2032, aiming to strengthen its financial position.
Rapport Therapeutics, Inc. has announced a public offering of common stock to enhance its financial position and support ongoing projects.
Rapport Therapeutics, Inc. director Ramiro Sanchez acquires 3,600 shares, signaling confidence in the company's future within the pharmaceutical sector.
Rapport Therapeutics, Inc. director Paul M. Silva acquires 3,680 shares, signaling confidence in the company's growth and direction.
John M. Maraganore, a director at Rapport Therapeutics, acquires over 9,000 shares, signaling confidence in the company’s future.
Rapport Therapeutics, Inc. reports director Paul Steven M's acquisition of 35,714 shares, signaling confidence in the company's future.
Rapport Therapeutics CFO Troy Ignelzi acquires 5,500 shares, raising total holdings to 15,500 shares, signaling confidence in the company's future.
Rapport Therapeutics reports positive results from its Phase 2 trial of RAP-219 for bipolar mania, paving the way for Phase 3 trials in 2027.
254 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-005299 | 005-94532 | 261559155 | 34 | 9666 | |||
| 2026-11-04 | 10-Q | 10-Q | 0001193125-26-446217 | 001-42121 | 261520054 | 34 | 10565285 | 1 | 1 | |
| 2026-11-04 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-446202 | 001-42121 | 261520031 | 34 | 394501 | 1 | 1 |
| 2026-11-03 | 4 | 4 | 0001193125-26-445438 | 17405 | ||||||
| 2026-10-30 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-120789 | 13062 | ||||||
| 2026-10-30 | 8-K | 8-K | 1.01,2.02,2.03,3.02,9.01 | 0001193125-26-441851 | 001-42121 | 261508919 | 34 | 2668266 | 1 | 1 |
| 2026-10-30 | 424B5 | 424B5 | 0001193125-26-439869 | 333-294170 | 261504392 | 33 | 1460174 | 1 | 1 | |
| 2026-10-30 | 424B5 | 424B5 | 0001193125-26-439863 | 333-294170 | 261504386 | 33 | 967637 | 1 | 1 | |
| 2026-10-29 | 305B2 | 305B2 | 0001193125-26-437789 | 333-294170 | 261501772 | 33 | 162890 | |||
| 2026-10-28 | FWP | FWP | 0001193125-26-435057 | 333-294170 | 261492355 | 34 | 96049 | |||
| 2026-10-28 | FWP | FWP | 0001193125-26-435030 | 333-294170 | 261492297 | 34 | 28716 | |||
| 2026-10-28 | FWP | FWP | 0001193125-26-434838 | 333-294170 | 261492192 | 34 | 110836 | |||
| 2026-10-28 | FWP | FWP | 0001193125-26-434642 | 333-294170 | 261492069 | 34 | 26224 | |||
| 2026-10-27 | 424B5 | 424B5 | 0001193125-26-434382 | 333-294170 | 261491246 | 33 | 1321426 | |||
| 2026-10-27 | 424B5 | 424B5 | 0001193125-26-434371 | 333-294170 | 261491220 | 33 | 738481 | |||
| 2026-10-23 | 4 | 4 | 0001193125-26-430504 | 6710 | ||||||
| 2026-10-23 | 4 | 4 | 0001193125-26-430397 | 5043 | ||||||
| 2026-10-22 | 4 | 4 | 0001193125-26-429075 | 4638 | ||||||
| 2026-10-22 | 4 | 4 | 0001193125-26-429074 | 4470 | ||||||
| 2026-10-22 | 4 | 4 | 0001193125-26-429073 | 6006 | ||||||
| 2026-10-22 | 4 | 4 | 0001193125-26-429071 | 7162 | ||||||
| 2026-10-21 | 4 | 4 | 0001193125-26-428018 | 4522 | ||||||
| 2026-10-20 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-425647 | 001-42121 | 261470424 | 34 | 11096429 | 1 | 1 |
| 2026-10-08 | 4 | 4 | 0001193125-26-417919 | 8634 | ||||||
| 2026-10-06 | 144 | xsl144X01/primary_doc.xml | 0001958244-26-000649 | 001-42121 | 261445084 | 33 | 14238 | |||
| 2026-10-01 | 4 | 4 | 0001193125-26-410734 | 7210 | ||||||
| 2026-09-30 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-009884 | 001-42121 | 261427389 | 33 | 4752 | |||
| 2026-09-24 | 4 | 4 | 0001193125-26-401017 | 10037 | ||||||
| 2026-09-09 | 4 | 4 | 0001193125-26-386436 | 8634 | ||||||
| 2026-08-26 | 4 | 4 | 0001193125-26-368285 | 6711 | ||||||
| 2026-08-26 | 4 | 4 | 0001193125-26-368244 | 9151 | ||||||
| 2026-08-25 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-008670 | 001-42121 | 261316188 | 33 | 6376 | |||
| 2026-08-24 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-008594 | 001-42121 | 261310897 | 33 | 5652 | |||
| 2026-08-20 | 4 | 4 | 0001193125-26-359189 | 4784 | ||||||
| 2026-08-19 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-008426 | 001-42121 | 261295851 | 33 | 4939 | |||
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-352285 | 005-94532 | 261281784 | 34 | 15367 | |||
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-003693 | 005-94532 | 261279717 | 34 | 9631 | |||
| 2026-08-12 | 4 | 4 | 0001193125-26-346995 | 14408 | ||||||
| 2026-08-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001562230-26-000114 | 005-94532 | 261265786 | 34 | 7681 | |||
| 2026-08-05 | 10-Q | 10-Q | 0001193125-26-333862 | 001-42121 | 261241351 | 34 | 9774140 | 1 | 1 | |
| 2026-08-05 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-333853 | 001-42121 | 261241337 | 34 | 464548 | 1 | 1 |
| 2026-07-29 | 4 | 4 | 0001193125-26-323637 | 9180 | ||||||
| 2026-07-15 | 4 | 4 | 0001193125-26-304786 | 9699 | ||||||
| 2026-07-01 | 4 | 4 | 0001193125-26-292546 | 11058 | ||||||
| 2026-07-01 | 4 | 4 | 0001193125-26-292519 | 9699 | ||||||
| 2026-06-30 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006648 | 001-42121 | 261140977 | 33 | 4752 | |||
| 2026-06-29 | 144 | xsl144X01/primary_doc.xml | 0001958244-26-000411 | 001-42121 | 261136453 | 33 | 5333 | |||
| 2026-06-10 | 4 | 4 | 0001193125-26-266155 | 5360 | ||||||
| 2026-06-10 | 4 | 4 | 0001193125-26-266147 | 5403 | ||||||
| 2026-06-10 | 4 | 4 | 0001193125-26-266129 | 5412 | ||||||
| 2026-06-10 | 4 | 4 | 0001193125-26-266099 | 5413 | ||||||
| 2026-06-10 | 4 | 4 | 0001193125-26-266095 | 5367 | ||||||
| 2026-06-10 | 4 | 4 | 0001193125-26-266090 | 5413 | ||||||
| 2026-06-10 | 4 | 4 | 0001193125-26-266086 | 5414 | ||||||
| 2026-06-10 | 4 | 4 | 0001193125-26-266080 | 5426 | ||||||
| 2026-06-10 | 8-K | 8-K | 5.07 | 0001193125-26-265841 | 001-42121 | 261079783 | 34 | 183108 | 1 | 1 |
| 2026-05-28 | 4 | 4 | 0001193125-26-245259 | 15713 | ||||||
| 2026-05-27 | 144 | xsl144X01/primary_doc.xml | 0001974078-26-000199 | 001-42121 | 261022450 | 33 | 7115 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-002222 | 005-94532 | 26985283 | 34 | 9660 | |||
| 2026-05-13 | 4 | 4 | 0001193125-26-222185 | 15709 | ||||||
| 2026-05-11 | 4 | 4 | 0001193125-26-217092 | 17674 | ||||||
| 2026-05-11 | 144 | xsl144X01/primary_doc.xml | 0001974078-26-000178 | 001-42121 | 26963592 | 33 | 6585 | |||
| 2026-05-08 | 144 | xsl144X01/primary_doc.xml | 0001974078-26-000173 | 001-42121 | 26959409 | 33 | 5948 | |||
| 2026-05-07 | 144 | xsl144X01/primary_doc.xml | 0001974078-26-000168 | 001-42121 | 26954400 | 33 | 5299 | |||
| 2026-05-07 | 10-Q | 10-Q | 0001193125-26-210355 | 001-42121 | 26950887 | 34 | 8982683 | 1 | 1 | |
| 2026-05-07 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-210324 | 001-42121 | 26950843 | 34 | 474365 | 1 | 1 |
| 2026-04-23 | ARS | ARS | 0001193125-26-171842 | 001-42121 | 26885559 | 34 | 8388555 | |||
| 2026-04-23 | DEFA14A | DEFA14A | 0001193125-26-171836 | 001-42121 | 26885543 | 34 | 243029 | |||
| 2026-04-23 | DEF 14A | DEF 14A | 0001193125-26-171828 | 001-42121 | 26885537 | 34 | 954693 | 1 | 1 | |
| 2026-04-21 | 4 | 4 | 0001193125-26-167636 | 15708 | ||||||
| 2026-04-21 | 4 | 4 | 0001193125-26-167091 | 5303 | ||||||
| 2026-04-21 | 8-K | 8-K | 7.01,8.01 | 0001193125-26-167078 | 001-42121 | 26880231 | 34 | 26510846 | 1 | 1 |
| 2026-04-17 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003609 | 001-42121 | 26872148 | 33 | 8544 | |||
| 2026-04-17 | 144 | xsl144X01/primary_doc.xml | 0001974078-26-000144 | 001-42121 | 26871912 | 33 | 4680 | |||
| 2026-04-14 | 4 | 4 | 0001193125-26-154908 | 8630 | ||||||
| 2026-04-13 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003401 | 001-42121 | 26858221 | 33 | 7099 | |||
| 2026-04-10 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003382 | 001-42121 | 26855376 | 33 | 6383 | |||
| 2026-04-09 | 4 | 4 | 0001193125-26-149725 | 4783 | ||||||
| 2026-04-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003340 | 001-42121 | 26849198 | 33 | 5494 | |||
| 2026-03-31 | 4 | 4 | 0001193125-26-134684 | 7209 | ||||||
| 2026-03-30 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003074 | 001-42121 | 26813291 | 33 | 5443 | |||
| 2026-03-26 | 4 | 4 | 0001193125-26-126410 | 5303 | ||||||
| 2026-03-25 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002990 | 001-42121 | 26792737 | 33 | 5641 | |||
| 2026-03-10 | S-3ASR | S-3ASR | 0001193125-26-099421 | 333-294170 | 26737299 | 33 | 1570834 | 1 | 1 | |
| 2026-03-10 | S-8 | S-8 | 0001193125-26-099377 | 333-294169 | 26737244 | 33 | 302942 | 1 | 1 | |
| 2026-03-10 | 10-K | 10-K | 0001193125-26-099360 | 001-42121 | 26737218 | 34 | 23154864 | 1 | 1 | |
| 2026-03-10 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-099336 | 001-42121 | 26737170 | 34 | 537846 | 1 | 1 |
| 2026-03-09 | 4 | 4 | 0001193125-26-098488 | 5091 | ||||||
| 2026-03-05 | 144 | xsl144X01/primary_doc.xml | 0001193125-26-094361 | 001-42121 | 26727710 | 33 | 4418 | |||
| 2026-02-19 | 4 | 4 | 0001193125-26-059886 | 13027 | ||||||
| 2026-02-19 | 4 | 4 | 0001193125-26-059883 | 12957 | ||||||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-26-001034 | 005-94532 | 26640026 | 34 | 9576 | |||
| 2026-02-04 | 4 | 4 | 0001193125-26-037618 | 5337 | ||||||
| 2026-02-04 | 4 | 4 | 0001193125-26-037603 | 5335 | ||||||
| 2026-02-04 | 4 | 4 | 0001193125-26-037587 | 5319 | ||||||
| 2026-02-04 | 4 | 4 | 0001193125-26-037581 | 5347 | ||||||
| 2026-02-04 | 4 | 4 | 0001193125-26-037570 | 5322 | ||||||
| 2026-02-04 | 4 | 4 | 0001193125-26-037529 | 5330 | ||||||
| 2026-01-22 | 4 | 4 | 0001193125-26-019820 | 8995 | ||||||
| 2026-01-21 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-26-000711 | 005-94532 | 26545874 | 34 | 10874 | |||
| 2026-01-16 | 4 | 4 | 0001193125-26-015350 | 6544 | ||||||
| 2026-01-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-000482 | 001-42121 | 26536614 | 33 | 7000 | |||
| 2026-01-07 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-005499 | 001-42121 | 26514100 | 34 | 195676 | 1 | 1 |
| 2026-01-07 | 424B5 | 424B5 | 0001193125-26-005482 | 333-288444 | 26514073 | 33 | 482964 | |||
| 2026-01-07 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-005446 | 001-42121 | 26513974 | 34 | 25586785 | 1 | 1 |
| 2026-01-05 | 4 | 4 | 0001193125-26-002470 | 6855 | ||||||
| 2026-01-05 | 4 | 4 | 0001193125-26-002469 | 6565 | ||||||
| 2026-01-02 | 144 | xsl144X01/primary_doc.xml | 0001193125-26-001213 | 001-42121 | 26503624 | 33 | 6248 | |||
| 2026-01-02 | 144 | xsl144X01/primary_doc.xml | 0001193125-26-001211 | 001-42121 | 26503615 | 33 | 4409 | |||
| 2025-12-18 | 4 | 4 | 0001193125-25-324826 | 17059 | ||||||
| 2025-12-17 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-010475 | 001-42121 | 251579643 | 33 | 7731 | |||
| 2025-12-17 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-010465 | 001-42121 | 251579604 | 33 | 7708 | |||
| 2025-12-16 | 4 | 4 | 0001193125-25-321142 | 7064 | ||||||
| 2025-12-01 | 4 | 4 | 0001193125-25-303910 | 8945 | ||||||
| 2025-11-18 | 4 | 4 | 0001193125-25-286218 | 13028 | ||||||
| 2025-11-18 | 4 | 4 | 0001193125-25-286212 | 7065 | ||||||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-25-004952 | 005-94532 | 251483868 | 34 | 10414 | |||
| 2025-11-06 | 10-Q | 10-Q | 0001193125-25-268096 | 001-42121 | 251456163 | 34 | 10330475 | 1 | 1 | |
| 2025-11-06 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-268072 | 001-42121 | 251456128 | 34 | 478436 | 1 | 1 |
| 2025-10-22 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000904454-25-000502 | 005-94532 | 251410807 | 34 | 9203 | |||
| 2025-10-16 | 4 | 4 | 0001193125-25-241475 | 7065 | ||||||
| 2025-10-16 | 4 | 4 | 0001193125-25-241472 | 13025 | ||||||
| 2025-10-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-007977 | 001-42121 | 251395089 | 33 | 6305 | |||
| 2025-09-19 | 4 | 4 | 0001193125-25-209062 | 13029 | ||||||
| 2025-09-18 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001104659-25-091350 | 005-94532 | 251324444 | 34 | 63215 | |||
| 2025-09-17 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-007282 | 001-42121 | 251320385 | 33 | 4817 | |||
| 2025-09-17 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-007277 | 001-42121 | 251320366 | 33 | 4849 | |||
| 2025-09-17 | 4 | 4 | 0001193125-25-206203 | 7065 | ||||||
| 2025-09-15 | 4 | 4 | 0001193125-25-203540 | 4895 | ||||||
| 2025-09-15 | 4 | 4 | 0001193125-25-203537 | 7385 | ||||||
| 2025-09-11 | 4 | 4 | 0000950170-25-114325 | 4331 | ||||||
| 2025-09-10 | 8-K | 8-K | 1.01,9.01 | 0001193125-25-200205 | 001-42121 | 251306643 | 34 | 446511 | 1 | 1 |
| 2025-09-10 | 424B5 | 424B5 | 0001193125-25-200200 | 333-288444 | 251306627 | 33 | 779341 | |||
| 2025-09-10 | 4 | 4 | 0001839046-25-000004 | 8427 | ||||||
| 2025-09-08 | 424B5 | 424B5 | 0001193125-25-198453 | 333-288444 | 251300843 | 33 | 799972 | |||
| 2025-09-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-006846 | 001-42121 | 251300312 | 33 | 4991 | |||
| 2025-09-08 | 8-K | 8-K | 8.01,9.01 | 0001193125-25-198322 | 001-42121 | 251299990 | 34 | 142831 | 1 | 1 |
| 2025-09-08 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-197610 | 001-42121 | 251298457 | 34 | 10801278 | 1 | 1 |
| 2025-08-18 | 4 | 4 | 0000950170-25-109838 | 7062 | ||||||
| 2025-08-07 | 10-Q | 10-Q | 0000950170-25-104565 | 001-42121 | 251191599 | 34 | 10225835 | 1 | 1 | |
| 2025-08-07 | 8-K | 8-K | 2.02,7.01,9.01 | 0000950170-25-104557 | 001-42121 | 251191574 | 34 | 19325407 | 1 | 1 |
| 2025-07-16 | 4 | 4 | 0000950170-25-096268 | 5142 | ||||||
| 2025-07-09 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-002211 | 333-288445 | 251114725 | 33 | 1748 | ||
| 2025-07-09 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-002210 | 333-288444 | 251114724 | 33 | 1748 | ||
| 2025-07-07 | CORRESP | filename1.htm | 0001193125-25-156166 | 6478 | ||||||
| 2025-07-07 | CORRESP | filename1.htm | 0001193125-25-156162 | 6388 | ||||||
| 2025-07-07 | UPLOAD | filename1.pdf | 0000000000-25-007103 | 333-288445 | 40079 | |||||
| 2025-07-07 | UPLOAD | filename1.pdf | 0000000000-25-007101 | 333-288444 | 40084 | |||||
| 2025-07-01 | S-3 | S-3 | 0001193125-25-153417 | 333-288445 | 251094139 | 33 | 279140 | |||
| 2025-07-01 | S-3 | S-3 | 0001193125-25-153415 | 333-288444 | 251094137 | 33 | 1368766 | |||
| 2025-06-18 | 8-K | 8-K | 5.07 | 0000950170-25-087921 | 001-42121 | 251057344 | 34 | 182694 | 1 | 1 |
| 2025-06-18 | 4 | 4 | 0000950170-25-087904 | 5289 | ||||||
| 2025-06-18 | 4 | 4 | 0000950170-25-087903 | 5277 | ||||||
| 2025-06-18 | 4 | 4 | 0000950170-25-087902 | 5223 | ||||||
| 2025-06-18 | 4 | 4 | 0000950170-25-087901 | 5230 | ||||||
| 2025-06-18 | 4 | 4 | 0000950170-25-087900 | 5266 | ||||||
| 2025-06-18 | 4 | 4 | 0000950170-25-087899 | 5299 | ||||||
| 2025-06-18 | 4 | 4 | 0000950170-25-087898 | 5275 | ||||||
| 2025-06-18 | 4 | 4 | 0000950170-25-087897 | 5141 | ||||||
| 2025-06-18 | 4 | 4 | 0000950170-25-087896 | 5272 | ||||||
| 2025-06-16 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-004362 | 001-42121 | 251050440 | 33 | 6189 | |||
| 2025-06-02 | 8-K | 8-K | 7.01,8.01,9.01 | 0000950170-25-080247 | 001-42121 | 251014982 | 34 | 27218937 | 1 | 1 |
| 2025-05-19 | 4 | 4 | 0000950170-25-074409 | 5152 | ||||||
| 2025-05-08 | 10-Q | 10-Q | 0000950170-25-066393 | 001-42121 | 25923886 | 34 | 9574228 | 1 | 1 | |
| 2025-05-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-066376 | 001-42121 | 25923837 | 34 | 501038 | 1 | 1 |
| 2025-04-24 | ARS | ARS | 0001193125-25-092144 | 001-42121 | 25863454 | 34 | 14600093 | |||
| 2025-04-24 | DEFA14A | DEFA14A | 0001193125-25-092139 | 001-42121 | 25863446 | 34 | 106831 | |||
| 2025-04-24 | DEF 14A | DEF 14A | 0001193125-25-092133 | 001-42121 | 25863439 | 34 | 1085642 | 1 | 1 | |
| 2025-04-16 | 4 | 4 | 0000950170-25-054819 | 5153 | ||||||
| 2025-04-03 | 4 | 4 | 0000950170-25-050557 | 5394 | ||||||
| 2025-03-17 | 4 | 4 | 0000950170-25-040447 | 5162 | ||||||
| 2025-03-14 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-001860 | 001-42121 | 25740292 | 33 | 4765 | |||
| 2025-03-13 | 4 | 4 | 0000950170-25-038878 | 5769 | ||||||
| 2025-03-13 | 4 | 4 | 0000950170-25-038855 | 4916 | ||||||
| 2025-03-11 | S-8 | S-8 | 0000950170-25-036832 | 333-285697 | 25725881 | 33 | 303465 | 1 | 1 | |
| 2025-03-11 | 10-K | 10-K | 0000950170-25-036828 | 001-42121 | 25725859 | 34 | 30337088 | 1 | 1 | |
| 2025-03-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-036822 | 001-42121 | 25725845 | 34 | 568639 | 1 | 1 |
| 2025-03-05 | 4 | 4 | 0000950170-25-033797 | 4930 | ||||||
| 2025-03-05 | 3 | 3 | 0000950170-25-033796 | 14610 | ||||||
| 2025-03-03 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-043405 | 001-42121 | 25693762 | 34 | 16865478 | 1 | 1 |
| 2025-02-13 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000950170-25-019904 | 005-94532 | 25620451 | 34 | 15159 | |||
| 2025-02-04 | 4 | 4 | 0000950170-25-013754 | 5340 | ||||||
| 2025-02-04 | 4 | 4 | 0000950170-25-013753 | 5368 | ||||||
| 2025-02-04 | 4 | 4 | 0000950170-25-013752 | 5343 | ||||||
| 2025-02-04 | 4 | 4 | 0000950170-25-013751 | 5356 | ||||||
| 2025-02-04 | 4 | 4 | 0000950170-25-013750 | 5351 | ||||||
| 2025-01-10 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-004045 | 001-42121 | 25520254 | 34 | 199186 | 1 | 1 |
| 2024-11-14 | SC 13G | ARCH VENTURE FUND XII, L.P. - RAPPORT THERAPEUTICS, INC. -- SCH 13G | 0001072613-24-000885 | 005-94532 | 241464248 | 34 | 231976 | |||
| 2024-11-14 | SC 13G/A | cormorant-rapp093024a1.htm | 0001172661-24-005064 | 005-94532 | 241460814 | 34 | 86364 | |||
| 2024-11-13 | SC 13G | SEC SCHEDULE 13G | 0001562230-24-000082 | 005-94532 | 241452622 | 34 | 18289 | |||
| 2024-11-12 | SC 13G/A | filing.txt | 0000315066-24-002916 | 005-94532 | 241445000 | 34 | 8254 | |||
| 2024-11-07 | 4 | 4 | 0000950170-24-123611 | 5339 | ||||||
| 2024-11-07 | 4 | 4 | 0000950170-24-123610 | 5328 | ||||||
| 2024-11-07 | 4 | 4 | 0000950170-24-123607 | 5334 | ||||||
| 2024-11-07 | 4 | 4 | 0000950170-24-123600 | 5409 | ||||||
| 2024-11-07 | 3 | 3 | 0000950170-24-123598 | 17450 | ||||||
| 2024-11-07 | 3 | 3 | 0000950170-24-123593 | 17457 | ||||||
| 2024-11-07 | 3 | 3 | 0000950170-24-123588 | 17912 | ||||||
| 2024-11-07 | 3 | 3 | 0000950170-24-123585 | 18874 | ||||||
| 2024-11-07 | 10-Q | 10-Q | 0000950170-24-122801 | 001-42121 | 241433182 | 34 | 8974220 | 1 | 1 | |
| 2024-11-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-122792 | 001-42121 | 241433146 | 34 | 375082 | 1 | 1 |
| 2024-10-18 | SC 13G | s13g_093024-rapportthera.htm | 0000904454-24-000538 | 005-94532 | 241381506 | 34 | 51920 | |||
| 2024-08-08 | 10-Q | 10-Q | 0000950170-24-093334 | 001-42121 | 241186089 | 34 | 9118562 | 1 | 1 | |
| 2024-08-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-093321 | 001-42121 | 241186042 | 34 | 457211 | 1 | 1 |
| 2024-07-26 | SEC STAFF LETTER | filename1.pdf | 9999999997-24-003356 | 63771 | ||||||
| 2024-07-10 | SC 13G | filing.txt | 0000315066-24-001831 | 005-94532 | 241108969 | 34 | 8033 | |||
| 2024-07-03 | 4 | OWNERSHIP DOCUMENT | 0001104659-24-077868 | 30902 | ||||||
| 2024-06-24 | SC 13G/A | RAPPORT_V2.txt | 0000769993-24-000280 | 005-94532 | 241066004 | 34 | 49167 | |||
| 2024-06-21 | SC 13G | RAPPORT.txt | 0000769993-24-000277 | 005-94532 | 241061157 | 34 | 48973 | |||
| 2024-06-20 | SC 13G | sc13g.htm | 0000929638-24-002235 | 005-94532 | 241056124 | 34 | 183684 | |||
| 2024-06-14 | SC 13D | SC 13D | 0001104659-24-071732 | 005-94532 | 241044565 | 34 | 143029 | |||
| 2024-06-10 | 4 | 4 | 0000950170-24-071543 | 19831 | ||||||
| 2024-06-10 | 4 | 4 | 0000950170-24-071541 | 5393 | ||||||
| 2024-06-10 | 4 | 4 | 0000950170-24-071540 | 5375 | ||||||
| 2024-06-10 | 4 | 4 | 0000950170-24-071539 | 5384 | ||||||
| 2024-06-10 | 4 | 4 | 0000950170-24-071538 | 5409 | ||||||
| 2024-06-10 | 4 | 4 | 0000950170-24-071537 | 23404 | ||||||
| 2024-06-10 | 4 | 4 | 0000950170-24-071533 | 5400 | ||||||
| 2024-06-10 | 4 | 4 | 0000950170-24-071532 | 18619 | ||||||
| 2024-06-10 | 4 | 4 | 0000950170-24-071527 | 5399 | ||||||
| 2024-06-10 | 8-K | 8-K | 1.01,3.02,5.03,9.01 | 0001193125-24-158327 | 001-42121 | 241032748 | 34 | 430460 | ||
| 2024-06-07 | S-8 | S-8 | 0001193125-24-157474 | 333-280058 | 241030353 | 33 | 90040 | |||
| 2024-06-07 | 424B4 | 424B4 | 0001193125-24-157358 | 333-279486 | 241029553 | 33 | 4530313 | |||
| 2024-06-06 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2024-06-06 16:00:00 | 9999999995-24-001768 | 333-279486 | 241027125 | 33 | 1765 | ||
| 2024-06-06 | 3 | 3 | 0000950170-24-070115 | 14545 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070095 | 16183 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070092 | 17898 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070091 | 14476 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070086 | 17163 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070084 | 16975 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070083 | 19093 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070078 | 17837 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070077 | 17875 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070076 | 15741 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070071 | 15789 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070069 | 17726 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070065 | 19906 | ||||||
| 2024-06-06 | 3 | 3 | 0000950170-24-070063 | 17158 | ||||||
| 2024-06-06 | CERT | 8A_Cert_RAPP.pdf | 0001354457-24-000394 | 001-42121 | 241024636 | 34 | 213202 | |||
| 2024-06-04 | 8-A12B | 8-A12B | 0001193125-24-154251 | 001-42121 | 241018058 | 34 | 14848 | |||
| 2024-06-04 | CORRESP | filename1.htm | 0001193125-24-154245 | 10904 | ||||||
| 2024-06-04 | CORRESP | filename1.htm | 0001193125-24-154232 | 6156 | ||||||
| 2024-06-03 | CORRESP | filename1.htm | 0001193125-24-152304 | 23200 | ||||||
| 2024-06-03 | S-1/A | S-1/A | 0001193125-24-152294 | 333-279486 | 241011898 | 33 | 5774902 | |||
| 2024-05-29 | CORRESP | filename1.htm | 0001193125-24-149345 | 82411 | ||||||
| 2024-05-24 | UPLOAD | filename1.pdf | 0000000000-24-006054 | 377-07153 | 43249 | |||||
| 2024-05-17 | CORRESP | filename1.htm | 0001193125-24-141723 | 31329 | ||||||
| 2024-05-17 | S-1 | S-1 | 0001193125-24-141704 | 333-279486 | 24959463 | 33 | 6842884 | |||
| 2024-05-13 | UPLOAD | filename1.pdf | 0000000000-24-005439 | 377-07153 | 44954 | |||||
| 2024-05-03 | SEC STAFF LETTER | filename1.pdf | 9999999997-24-002569 | 65186 | ||||||
| 2024-04-29 | DRSLTR | filename1.htm | 0000950123-24-003595 | 42734 | ||||||
| 2024-04-29 | DRS/A | filename1.htm | 0000950123-24-003594 | 377-07153 | 24888066 | 33 | 4724117 | |||
| 2024-04-24 | UPLOAD | filename1.pdf | 0000000000-24-004587 | 377-07153 | 52570 | |||||
| 2024-03-27 | DRS | filename1.htm | 0000950123-24-003008 | 377-07153 | 24790880 | 33 | 4590492 |
One latest value per concept from companyfacts (192 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 59.28M | 2026-11-02 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 275.84M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 20,010 | 2026-10-30 | 424B5 | 2026-10-30 | 0001193125-26-439863 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 20,010 | 2026-10-30 | 424B5 | 2026-10-30 | 0001193125-26-439863 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 230.00M | 2026-10-30 | 424B5 | 2026-10-30 | 0001193125-26-439863 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-30 | 424B5 | 2026-10-30 | 0001193125-26-439863 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-10-30 | 424B5 | 2026-10-30 | 0001193125-26-439863 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 1.72M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 171,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 370,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 16.26M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 1.79M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 2.12M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -2.12M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 745.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 7.63M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 21.80M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | AllowanceForDoubtfulAccountsReceivableCurrent | Accounts Receivable, Allowance for Credit Loss, Current | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 5.61M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | AssetImpairmentCharges | Asset Impairment Charges | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | Assets | Assets | USD | 418.56M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 407.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 2.12M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 322.39M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | USD | 228.31M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 320.27M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 74.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 395.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 74.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | 22.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 500.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 48.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 48.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 48,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -119.37M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 22.15M | 2024-06-07 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | CurrentFederalStateAndLocalTaxExpenseBenefit | Current Federal, State and Local, Tax Expense (Benefit) | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | DeferredFederalIncomeTaxExpenseBenefit | Deferred Federal Income Tax Expense (Benefit) | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | DeferredFederalStateAndLocalTaxExpenseBenefit | Deferred Federal, State and Local, Tax Expense (Benefit) | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | DeferredFinanceCostsNet | Debt Issuance Costs, Net | USD | 16.80M | 2024-06-30 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 2.54M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 500,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | DeferredStateAndLocalIncomeTaxExpenseBenefit | Deferred State and Local Income Tax Expense (Benefit) | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction | Deferred Tax Assets, Deferred Gain on Sale Leaseback Transaction | USD | 2.81M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 62.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsInProcessResearchAndDevelopment | Deferred Tax Assets, in Process Research and Development | USD | 34.01M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 10.20M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 10.59M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other | USD | 20,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 1.79M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other | USD | 1.63M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 59.46M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | Depreciation | Depreciation | USD | 600,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 637,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | Dividends | Dividends | USD | 0 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-06 | 0001193125-25-268096 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -2.46 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -2.46 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.225 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.006 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent | pure | 0.036 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | -0.017 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent | pure | -0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.038 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 5.65M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 30.31M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -78.31M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 25.13M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -23.41M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 684,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | IncomeTaxReconciliationOtherReconcilingItems | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount | USD | 9,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 4.25M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -2.46M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | 171,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities | USD | 4.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | -344,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 3.20M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 12.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | LeaseCost | Lease, Cost | USD | 2.81M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 13.41M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 821,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 3.48M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 879,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 2.59M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 2.86M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 2.79M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 1.93M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | Liabilities | Liabilities | USD | 27.37M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 418.56M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 20.30M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | LossContingencyAccrualAtCarryingValue | Loss Contingency Accrual | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | NetAssetValuePerShare | Net Asset Value Per Share | USD/shares | 1 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 3.65M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 114.61M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -96.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -116.71M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -116.71M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 | Noncash or Part Noncash Acquisition, Fixed Assets Acquired | USD | 11,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 12.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | OciEquityMethodInvestmentAfterTaxParent | OciEquityMethodInvestmentAfterTaxParent | USD | -2.66M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 149.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -129.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 2.75M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 11.48M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 2.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 7.07M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 1.21M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 8.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 1.78M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.072 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 214,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 1.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | USD | -2.66M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | PaymentsOfFinancingCosts | Payments of Financing Costs | USD | 453,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 58,000 | 2023-01-01 | 2023-06-30 | 2024 | Q2 | 10-Q | 2024-08-08 | 0000950170-24-093334 |
| us-gaap | PaymentsToAcquireInvestments | Payments to Acquire Investments | USD | 84.44M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 164,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | PreferredStockConvertibleSharesIssuable | PreferredStockConvertibleSharesIssuable | shares | 22.15M | 2024-03-31 | 2025 | Q1 | 10-Q | 2025-05-08 | 0000950170-25-066393 | |
| us-gaap | PreferredStockDividendRatePercentage | Preferred Stock, Dividend Rate, Percentage | pure | 0.08 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 12.08M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 269.40M | 2025-09-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 54,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | ProceedsFromIssuanceOfConvertiblePreferredStock | Proceeds from Issuance of Convertible Preferred Stock | USD | 63.91M | 2024-01-01 | 2024-09-30 | 2025 | Q3 | 10-Q | 2025-11-06 | 0001193125-25-268096 |
| us-gaap | ProceedsFromSaleMaturityAndCollectionsOfInvestments | Proceeds from Sale, Maturity and Collection of Investments | USD | 188.73M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ProceedsFromSaleOfPropertyPlantAndEquipment | Proceeds from Sale of Property, Plant, and Equipment | USD | 401,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ProceedsFromSaleOfShortTermInvestments | Proceeds from Sale of Short-term Investments | USD | 10.07M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 4.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -116.71M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 4.08M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 1.96M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 118.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 105,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -351.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 20.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | SellingGeneralAndAdministrativeExpense | Selling, General and Administrative Expense | USD | 30.66M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 21.80M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | USD/shares | 0.74 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 0.903 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.823 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.044 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.038 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 71.01M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 3.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 12.34 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 201,239 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 2.23M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 135.18M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 7.95M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 16.72 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 135.18M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 7.95M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 16.72 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 11.36 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 21.27 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 28.92 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | ShortTermInvestments | Short-term Investments | USD | 320.27M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | ShortTermLeaseCost | Short-term Lease, Cost | USD | 66,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 391.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.117 | 2024-05-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 | |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 361,827 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments | Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments | USD | 7.34M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 269.44M | 2025-07-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | USD | 54,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-11 | 0000950170-25-036828 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 1.71M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | StockRepurchasedDuringPeriodValue | Stock Repurchased During Period, Value | USD | 5,000 | 2026-01-01 | 2026-03-31 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 234.74M | 2024-03-31 | 2025 | Q1 | 10-Q | 2025-05-08 | 0000950170-25-066393 | |
| us-gaap | TemporaryEquityLiquidationPreference | Temporary Equity, Liquidation Preference | USD | 250.18M | 2024-03-31 | 2025 | Q1 | 10-Q | 2025-05-08 | 0000950170-25-066393 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 189.61M | 2024-03-31 | 2025 | Q1 | 10-Q | 2025-05-08 | 0000950170-25-066393 | |
| us-gaap | TemporaryEquitySharesIssued | Temporary Equity, Shares Issued | shares | 189.61M | 2024-03-31 | 2025 | Q1 | 10-Q | 2025-05-08 | 0000950170-25-066393 | |
| us-gaap | TemporaryEquitySharesOutstanding | Temporary Equity, Shares Outstanding | shares | 189.61M | 2024-03-31 | 2025 | Q1 | 10-Q | 2025-05-08 | 0000950170-25-066393 | |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | -29.25M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | VariableLeaseCost | Variable Lease, Cost | USD | 54,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-10 | 0001193125-26-099360 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 47.49M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 47.49M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001193125-26-446217 |